Reply to: Risk factors for disease progression in fibrotic hypersensitivity pneumonitis
- PMID: 36549715
- DOI: 10.1183/13993003.02261-2022
Reply to: Risk factors for disease progression in fibrotic hypersensitivity pneumonitis
Conflict of interest statement
Conflict of interest: M.M. Farooqi has nothing to disclose. N. Hambly reports grants from Boehringer Ingelheim and Janssen, and travel support and lecture honoraria from Boehringer Ingelheim, Janssen and Roche, outside the submitted work. C.J. Ryerson reports support for the present manuscript from Boehringer Ingelheim; grants from Boehringer Ingelheim, consulting fees from Boehringer Ingelheim, Pliant Therapeutics and Veracyte, lecture honoraria from Hoffmann-La Roche, Boehringer Ingelheim and Cipla, and travel support from Cipla and Boehringer Ingelheim, outside the submitted work. M. Kolb reports support for the present manuscript from Boehringer Ingelheim; grants from Boehringer Ingelheim, Pieris and Roche, consulting fees from Boehringer Ingelheim, Roche, Horizon, Cipla, Abbvie, Belerophon, Algernon and CSL Behring, lecture honoraria from Novartis, Boehringer Ingelheim and Roche, payment for expert testimony from Roche, advisory board participation with Covance and United Therapeutics, and reports a chief editor allowance from European Respiratory Society, outside the submitted work.
Comment on
-
Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry.Eur Respir J. 2022 Oct 6;60(4):2102571. doi: 10.1183/13993003.02571-2021. Print 2022 Oct. Eur Respir J. 2022. PMID: 35273032
-
Risk factors for disease progression in fibrotic hypersensitivity pneumonitis.Eur Respir J. 2023 Jan 27;61(1):2201706. doi: 10.1183/13993003.01706-2022. Print 2023 Jan. Eur Respir J. 2023. PMID: 36549705 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical